A Phase 4 interventional study of Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily and Rosuvastatin calcium10mg in Coronary Artery Disease and Angina Pectoris, sponsored by Kobe University. Status unknown at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-08-31.
Sponsored by Kobe University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Coronary Artery Disease by Kobe University — 1 open to participants now, 1 under way, none of them phase 3. Coronary Artery Disease · Kobe University.
Among the 10 studies in Coronary Artery Disease by Kobe University, this one is one of 3 that started in 2018, is one of 5 in phase 4, and was the 5th registered.
4,863 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →1 of the 10 studies in Coronary Artery Disease by Kobe University is open now, in 1 country. Recruiting first, the newest first:
Kobe University · Sites in Japan
Ages 20+
By country, each count listing its studies:
Of the 588 Coronary Artery Disease studies recruiting now, 402 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 124 across 3,010 interventional studies indexed under Coronary Artery Disease.
Median enrollment 50 across the 7 interventional studies, 72 across the 3 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Kobe University is the lead sponsor of 17 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Coronary Artery Disease by Kobe University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to verify whether additional administration of Alirocumab exerts a stronger stabilizing effect on the vulnerable plaque in CAD, compared with statin alone administration in patients receiving PCI. Therefore, the change in maxLCBI (4 mm) of the coronary artery 9 months after administration by addition administration of Alirocumab is evaluated as the main evaluation item as compared with statin administration alone for patients who have CAD and received PCI. Also, change of plaque properties is compared with baseline and evaluated. This study is a single-center, randomized, open-label study, using alirocumab, rosuvastatin as test drugs. Based on the findings obtained in this study, it is possible to clarify the mechanism of stabilization of the plaque in a patient with coronary artery disease, which in turn suppresses the progress of plaque in coronary artery disease, resulting in primary or secondary There is a possibility that it can contribute to prevention.
The investigators investigate the change in the maxLCBI (4 mm) value calculated by NIRS-IVUS at the time of PCI and at the treatment evaluation after 9 months compared with the group of Alirocumab(Alirocumab75mg/2week+losuvastatin10mg/daily) and standard treatment (losuvastatin10mg/daily alone). And also the investigators evaluate LCBI(lesion), Angle of a lipid core, EEM CSA, Lumen CSA, Minimum lumen diameter, Plaque burden, Lesion length by NIRS-IVUS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Alirocumab group is Alirocumab75mg/2week plus Rosuvastatin10mg/daily.
Drug: Alirocumab 75 MG/ML [Praluent]+ Rosuvastatin 10mg/daily
The standard therapy group is Rosuvastatin10mg/daily alone.
Drug: Rosuvastatin calcium10mg
Drug page: Alirocumab
Alirocumab group receive Alirocumab75mg/2week subcutaneous injection plus Rosuvastatin10mg/daily by oral for 9 months.
Rosuvastatin10mg/daily by oral for 9 months.
maxLCBI (4mm)
Time frame: baseline and 9 months
change amount of LCBI(lesion)
Time frame: baseline and 9 months
change amount of Angle of lipid core
Time frame: baseline and 9 months
change amount of LDL-Cholesterol level
Time frame: baseline and 9 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2018 (actual). Primary completion is estimated for Sep 2020, 29 months after the start.
Of 193 phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 58. This study's planned 29 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab
Kobe University